scholarly journals Survival and postoperative complication in daily practice after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer

2003 ◽  
Vol 2 (4) ◽  
pp. 558-562 ◽  
Author(s):  
F BARLESI
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Postoperative Complication ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Daily Practice ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia

scholarly journals Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy

2016 ◽  
Vol 101 (2) ◽  
pp. 451-458 ◽  
Author(s):  
Stephen R. Broderick ◽  
Aalok P. Patel ◽  
Traves D. Crabtree ◽  
Jennifer M. Bell ◽  
Daniel Morgansztern ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia

Endobronchial Valve Placement for Spontaneous Pneumothorax From Stage IIIA Non-Small Cell Lung Cancer Facilitates Neoadjuvant Therapy

2013 ◽  
Vol 96 (6) ◽  
pp. 2225-2227 ◽  
Author(s):  
Christopher R. Gilbert ◽  
Jennifer W. Toth ◽  
Jussuf T. Kaifi ◽  
Chandra P. Belani ◽  
John Varlotto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Spontaneous Pneumothorax ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Endobronchial Valve ◽  
Valve Placement

scholarly journals Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Caroline Y. Chen ◽  
Charlene M. Fares ◽  
Daniel Sanghoon Shin
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
African American Patient ◽  
Small Cell Lung ◽  
Stage Iiia

Abstract Introduction Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC). Case presentation Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadjuvant setting with concurrent radiation, followed by resection. The patient remains disease-free 4 months after surgery. Conclusion This case report suggests that osimertinib may be effective as neoadjuvant therapy in resectable stage III disease. Additionally, we provide a summary of previous case reports and ongoing clinical trials for neoadjuvant EGFR inhibition in stage III NSCLC patients.

Baseline SUVmax at PET-CT in Stage IIIA Non-small-cell Lung Cancer Patients Undergoing Surgery after Neoadjuvant Therapy

2012 ◽  
Vol 19 (4) ◽  
pp. 440-445 ◽  
Author(s):  
Ho Yun Lee ◽  
Kyung Soo Lee ◽  
Jungjae Park ◽  
Joungho Han ◽  
Byung-Tae Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Lung Cancer Patients ◽  
Pet Ct

scholarly journals Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer

2020 ◽  
Vol 109 (3) ◽  
pp. 842-847 ◽  
Author(s):  
Jonathan D. Rice ◽  
Justin Heidel ◽  
Jaimin R. Trivedi ◽  
Victor H. van Berkel
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neoadjuvant Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Surgical Timing
Sign in / Sign up

Export Citation Format

Share Document